Belite Bio (NASDAQ: BLTE)
Belite Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Belite Bio Company Info
Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
News & Analysis
Why Shares of Belite Bio Soared This Week
The clinical-stage biotech company bounced back from a 52-week low late last week.
Why Shares of Belite Bio Are Slumping Wednesday
The biopharmaceutical company announced a stock sale that's not great news to current investors.
3 Breakout Growth Stocks to Buy for the Long Haul
These three have had big-time share gains backed up by breakthrough science.
2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023
Find out how these stock rockets could continue their ascent.
3 Soaring Biotech Stocks That Could Climb Much Higher
These drugmakers have bucked the overall market's downward trend this year and expectations are still high.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.